Teva ADR earnings matched, revenue topped estimates

Investing.com – Teva ADR (NYSE: ) reported third quarter EPS of $0.60, in line with the analyst estimate of $0.60. Revenue for the quarter came in at $3.9B versus the consensus estimate of $3.72B.

Guidance

Teva ADR sees FY 2023 EPS of $2.25-$2.55 versus the analyst consensus of $2.28.

Teva ADR sees FY 2023 revenue of $15.10B-$15.50B versus the analyst consensus of $15.14B.

Teva ADR’s stock price closed at $9.04. It is down -7.57% in the last 3 months and down -0.44% in the last 12 months.

Teva ADR saw 2 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Teva ADR’s stock price’s past reactions to earnings here.

According to InvestingPro, Teva ADR’s Financial Health score is “good performance”.

Check out Teva ADR’s , and Teva ADR’s financials here.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar